Tricida Inc (NASDAQ:TCDA) SVP Dawn Parsell Otto Sells 5,000 Shares

Tricida Inc (NASDAQ:TCDA) SVP Dawn Parsell Otto sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $33.69, for a total transaction of $168,450.00. Following the completion of the transaction, the senior vice president now owns 1,500 shares of the company’s stock, valued at approximately $50,535. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Dawn Parsell Otto also recently made the following trade(s):

  • On Monday, July 29th, Dawn Parsell Otto sold 5,000 shares of Tricida stock. The stock was sold at an average price of $31.19, for a total transaction of $155,950.00.
  • On Wednesday, July 3rd, Dawn Parsell Otto sold 15,407 shares of Tricida stock. The stock was sold at an average price of $37.04, for a total transaction of $570,675.28.

Shares of TCDA traded down $0.43 during trading hours on Friday, hitting $34.06. 19,741 shares of the company were exchanged, compared to its average volume of 178,733. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -7.34 and a beta of 0.83. Tricida Inc has a fifty-two week low of $19.43 and a fifty-two week high of $42.80. The company has a quick ratio of 14.22, a current ratio of 14.23 and a debt-to-equity ratio of 0.11. The firm’s fifty day moving average is $33.16 and its 200 day moving average is $32.82.

Tricida (NASDAQ:TCDA) last released its earnings results on Thursday, August 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.12. Analysts anticipate that Tricida Inc will post -3.54 EPS for the current year.

Several hedge funds have recently made changes to their positions in TCDA. Quantamental Technologies LLC bought a new position in Tricida in the first quarter valued at about $39,000. Bank of Montreal Can bought a new position in shares of Tricida during the second quarter worth about $72,000. Marshall Wace North America L.P. raised its position in shares of Tricida by 99.0% during the first quarter. Marshall Wace North America L.P. now owns 2,591 shares of the company’s stock worth $100,000 after acquiring an additional 1,289 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Tricida during the first quarter worth about $143,000. Finally, BNP Paribas Arbitrage SA raised its position in shares of Tricida by 1,586.2% during the first quarter. BNP Paribas Arbitrage SA now owns 4,030 shares of the company’s stock worth $156,000 after acquiring an additional 3,791 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

Several research analysts recently weighed in on TCDA shares. Needham & Company LLC set a $50.00 price target on shares of Tricida and gave the stock a “buy” rating in a research report on Monday, August 12th. Zacks Investment Research downgraded shares of Tricida from a “hold” rating to a “sell” rating in a research report on Tuesday. Cowen reissued a “buy” rating and set a $50.00 price objective on shares of Tricida in a research report on Thursday, August 8th. Finally, Goldman Sachs Group started coverage on shares of Tricida in a research report on Wednesday, June 26th. They set a “buy” rating and a $48.00 price objective on the stock.

Tricida Company Profile

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

Further Reading: Call Option Volume

Insider Buying and Selling by Quarter for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.